Anzeige
Mehr »
Donnerstag, 24.07.2025 - Börsentäglich über 12.000 News
Gamechanger im Anmarsch? Analysten sehen noch Nachholpotenzial bei dieser Aktie!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JLMD | ISIN: US03168L1052 | Ticker-Symbol: 2DT
Tradegate
23.07.25 | 19:27
6,800 Euro
-1,45 % -0,100
1-Jahres-Chart
AMNEAL PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
AMNEAL PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
6,8006,90010:58
6,8006,90009:58

Aktuelle News zur AMNEAL PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoAmneal Pharmaceuticals announces unaudited preliminary Q2 revenue between $720M and $730M4
MoAmneal seeks to borrow $1.8 billion in new term loans, offers notes2
MoAmneal reports 3% revenue growth in Q2, advances deleveraging2
MoAmneal plant Refinanzierung über neue Kredite und Anleihen im Milliardenwert5
AMNEAL PHARMACEUTICALS Aktie jetzt für 0€ handeln
MoAmneal Pharmaceuticals LLC: Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results759- Results Reflect Continued Financial Strength and Deleveraging - BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today...
► Artikel lesen
MoAmneal Pharmaceuticals LLC: Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 20322
MoAmneal Pharmaceuticals, Inc. - 8-K, Current Report1
12.07.Amneal Pharmaceuticals (AMRX) Announces FDA Approval of Prednisolone Acetate Ophthalmic Suspension5
09.07.Amneal Pharmaceuticals LLC: Amneal to Report Second Quarter 2025 Results on August 5, 20253
25.06.Amneal Pharmaceuticals LLC: Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences114Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth...
► Artikel lesen
12.06.Amneal Pharma Gets FDA Approval For Prednisolone Acetate Ophthalmic Suspension-
12.06.Amneal Pharmaceuticals LLC: Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension171Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals...
► Artikel lesen
10.06.Amneal Pharmaceuticals bei Goldman Sachs Konferenz: Strategische Wachstumsvision5
06.06.Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space20
06.06.Goldman Sachs stuft Amneal Pharmaceuticals-Aktie mit neutraler Bewertung ein6
06.06.Goldman Sachs initiates Amneal Pharmaceuticals stock with neutral rating2
05.06.Amneal recalls 3 lots of a generic antibiotic after black spots found on tablets1
04.06.Amneal recalls oral antibiotic due to bacterial contamination1
21.05.DelveInsight Business Research, LLP: Migraine Market Enters New Era Following Satsuma Pharmaceuticals' ATZUMI and Amneal Pharmaceuticals' BREKIYA Regulatory Approval | DelveInsight365The approval of ATZUMI and BREKIYA is expected to significantly reshape the migraine market by introducing new, innovative treatment options. These therapies promise improved efficacy and...
► Artikel lesen
16.05.FDA approves Amneal's DHE migraine/cluster headache autoinjector2
Weiter >>
53 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1